Overview of Myozepam

Quick Facts

Property	Description
Active ingredient	Tetrazepam
Form	Oral tablets or film-coated tablets
Pharmacological class	Centrally acting muscle relaxant
Common use	Relief of muscle spasm and tension
Origin	Synthetic, 1,4-Benzodiazepin-2-one derivative

Myozepam is a prescription-only medicine primarily classified as a centrally acting muscle relaxant, distinguished by its active substance, Tetrazepam. This medicine is used in managing muscle tension and stiffness through its pharmacological properties. The product is consistently manufactured as a single-ingredient product for oral administration, typically supplied in the form of tablets or film-coated tablets.

What Type of Medicine is Myozepam (Tetrazepam)?

Myozepam is defined by its active ingredient, Tetrazepam, which is chemically recognized as a synthetic 1,4-Benzodiazepin-2-one derivative. This structure places it within the broader Benzodiazepine chemical class. However, its therapeutic positioning is specific: it is a centrally acting muscle relaxant, contrasting with other Benzodiazepines primarily used as anxiolytic or sedative agents. The compound possesses a unique chemical structure, including a substituted cyclohexenyl ring, which relates to its specialization for muscle relaxation. This differentiation ensures that the product’s effect is focused on managing muscle hyperactivity.

General Purpose and Effect of Myozepam

The general purpose of Myozepam is to alleviate the symptoms of involuntary muscle contraction, tension, and stiffness associated with various musculoskeletal disorders. For example, it is used to manage the discomfort of acute muscle contractures stemming from conditions like lower back strain. The drug works by enhancing the body's natural inhibitory nerve signaling, which reduces the excitability of motor neurons. This intervention in the central nervous system signaling serves to reduce hypertonia and improve comfort. The essential benefit is the restoration of a more relaxed state to the affected skeletal muscles by interrupting the signaling responsible for excessive muscle tone.

What side effects are possible with Myozepam?

Possible Side Effects and Safety Information

The safety profile of Myozepam (Tetrazepam) is officially documented through regulatory classifications that organize adverse reactions by frequency and affected organ system. The medicine’s most commonly reported adverse reactions are related to its action as a central nervous system (CNS) depressant. These include drowsiness, dizziness, and a reduction in muscle force, effects typically classified under the Nervous System Disorders and Musculoskeletal Disorders system-organ classes.

A central feature of the safety profile is the documented very rare risk of serious and potentially fatal Cutaneous Adverse Reactions (SCARs). These serious adverse events, classified under Skin and Subcutaneous Tissue Disorders, include Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and DRESS syndrome. Official regulatory reviews note that these severe skin reactions are unpredictable and can appear at any stage during treatment, including after short-term exposure.

Other serious adverse reactions documented in regulatory sources include severe hypersensitivity events, such as Anaphylactic shock, and hepatotoxicity, including liver failure, classified under Hepatobiliary Disorders. Safety information also notes that concomitant use with other CNS depressants, such as alcohol or opioids, increases the risk of profound sedation and respiratory depression.

Due to the risks associated with SCARs, the medicine's benefit-risk balance was formally determined by regulatory authorities to be unfavorable, leading to the suspension of marketing authorizations in certain regions. Precautionary use is noted for older adults and individuals with hepatic impairment, consistent with the safety requirements for its chemical class.

Overdose and Emergency Response

An overdose of Myozepam (Tetrazepam), consistent with its classification as a benzodiazepine, primarily results in dose-dependent Central Nervous System (CNS) depression. Documented clinical manifestations of an overdose range from mild symptoms such as somnolence, lethargy, confusion, and ataxia (impaired coordination) to more severe presentations. Additional signs documented in regulatory sources include hypotonia, slurred speech (dysarthria), and anterograde amnesia.

The most serious outcomes involve profound CNS and respiratory compromise. Severe toxicity is associated with progression to deep, prolonged coma, respiratory depression, and apnea. Regulatory agencies have documented that the risk of slowed or difficult breathing and death is significantly heightened when this medication is taken concurrently with other CNS depressants, notably opioid pain or cough medicines.

Immediate medical attention is required for any observed symptoms of unusual lightheadedness, extreme sleepiness, or slowed/difficult breathing. Management, as formally described in regulatory documents, consists of symptomatic and supportive care focused on stabilizing vital signs and maintaining airway patency, which may require artificial ventilation. While Flumazenil, a specific benzodiazepine antagonist, is available, official guidance cautions against its routine use in certain overdose scenarios due to documented risk factors, such as precipitating seizure activity. Clinical protocols specify observation requirements, noting that pediatric patients remaining asymptomatic after a four-hour observation period may be safely discharged.

Therapeutic Uses of Myozepam

What Myozepam Treats: Main Uses and Benefits

Myozepam (Tetrazepam) is relevant for easing symptoms related to heightened physiological activity and associated discomfort. Its therapeutic application is applied across domains where additional symptomatic support is needed. For example, its use includes the treatment of painful contractures, low back pain, and spasticity. The medication is commonly used across conditions presenting with acute episodes of musculoskeletal discomfort, relevant in clinical settings that involve acute or unstable symptom patterns.

The medication is applied in managing symptom clusters that may become intense or disruptive, specifically involuntary muscle contraction and spasms. It helps manage symptoms of increased neurological or muscular activity, such as severe muscle stiffness or hypertonia, in situations where patients experience noticeable physiological strain. Its use is relevant when supportive symptom management is appropriate to provide relief during difficult acute episodes.

“This medication contributes to improved comfort during periods of heightened symptoms, which supports general well-being during symptomatic phases.”

It assists with maintaining functional stability when symptoms interfere with routine activities, in situations where patients experience acute low back strain or painful contractures in rheumatology.

Quick Fact: Relief for Acute Muscle Tension and Spasm

Regulatory References

European Medicines Agency's review

Eligibility and Restrictions for Use

Myozepam (Tetrazepam) eligibility is defined by strict regulatory and clinical constraints found in official government labeling. The most significant restriction is the suspension of marketing authorizations across the European Union (EU) by the EMA due to concerns over the risk of serious skin reactions and limited efficacy. This action renders the use of Myozepam contraindicated for all populations in that region.

Populations for Whom Use is Contraindicated

Official labeling prohibits use for patients with:

Known hypersensitivity to Tetrazepam or other benzodiazepines.
Severe Respiratory Insufficiency or Sleep Apnea Syndrome.
Severe Hepatic Insufficiency.
Myasthenia Gravis.

Age and Life Stage Restrictions

Eligibility Status	Population Group	Regulatory Status
Not Recommended	Children and Adolescents	Insufficient data; use generally not advised.
Not Recommended	Pregnant or Lactating Women	Potential risks documented; substance is excreted into breast milk.
Conditional Use	Older Adults (Geriatric)	Requires special caution due to increased sensitivity.

The official eligibility profile is strictly defined by these mandatory exclusions, clarifying who must not use the medicine and under what restricted conditions it may be considered for the original labeled population of Adult Patients.

What should I know about interactions with other medicines?

The official regulatory interaction profile for Myozepam (Tetrazepam) is characterized by pharmacodynamic enhancement resulting in increased Central Nervous System (CNS) depression.

Interaction Scope

Classification	Official Regulatory Statement
Interacting Categories	Other Central Nervous System (CNS) Depressants, including Opioid pain or cough medicines and certain sedating agents.
Mechanistic Basis	Pharmacodynamic interaction that results in an additive or synergistic increase of CNS depressant effects.
Substance Interaction	Co-ingestion with Alcohol (Ethanol) is documented to amplify the CNS depressant outcomes, posing an increased risk of severe central nervous system compromise.
Population Note	Elderly patients are noted in official documentation as potentially more susceptible to the CNS depressant action and associated interaction risks.
Timing Rules	No mandatory timing separation rules are specified in regulatory documentation.

Official Interaction Statements

Co-administration with Opioid pain or cough medicines is officially documented to increase the risk of severe outcomes, including profound sedation, respiratory depression, and death.
Co-administration with other CNS depressants results in an increased risk and severity of sedation.

This structure defines Myozepam's interaction constraints based on the documented potential for compounding sedative and respiratory depressant effects, a significant caution within the drug's official regulatory labeling.

Mechanism of Action

Myozepam functions as a positive allosteric modulator (PAM) of the GABAA receptor, the primary inhibitory receptor in the central nervous system. Its selective binding occurs at a non-benzodiazepine allosteric site located on the receptor's gamma2 subunit. This binding interaction induces a conformational shift within the GABAA receptor complex.

This conformational change does not activate the receptor directly but enhances the receptor's affinity for the neurotransmitter GABA. Consequently, when GABA binds, the frequency of chloride ion channel opening increases. The resultant heightened chloride influx drives the hyperpolarization of the postsynaptic membrane. This molecular cascade elevates the inhibitory tone throughout the central nervous system, leading to a functional reduction in overall neuronal excitability and modulating downstream signaling pathways.

Dosage and Administration Information

How to Use Myozepam (Tetrazepam) – Official Administration Guidelines

Myozepam is a medication designated for oral administration, typically supplied as tablets or film-coated tablets, with a common strength of 50 mg. Usage follows established parameters that define the manner and duration of administration, ensuring the medicine is used in accordance with its labeled specifications.

Official Administration Protocol

The standard protocol involves starting with a low dose, generally 25 mg to 50 mg daily, which may be gradually adjusted upward based on the prescribed regimen. The established maintenance range generally does not exceed 150 mg per day, although the maximum labeled dose in some regions is cited up to 300 mg. Dosing is frequently initiated as a once-daily schedule, with the instruction to take the largest portion of the total daily dose in the evening or at bedtime. This specific timing is a core component of the administration schedule.

Treatment follows the principle of using the shortest possible duration, with standard guidelines specifying a maximum course of 3 weeks to 3 months. When cessation is necessary, a gradual reduction (tapering) of the dose is required to manage the transition off the medication.

Usage Instruction Domain	Official Labeled Principle
Route & Form	Oral administration (tablets)
Initiation Dose	Typically 25 mg to 50 mg daily
Timing Constraint	Largest dose administered in the evening
Duration Limit	Shortest duration possible (e.g., 3 weeks–3 months)

Population-Specific Use

Use in older adults requires a reduced initial dose and cautious management. Conversely, routine use of the medicine in children is generally not recommended or is restricted to the oversight of a specialist, reflecting the limitations established for this patient group.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Myozepam

This section describes the types of clinical studies that have been conducted on Myozepam (Tetrazepam), the outcomes that researchers measured, and the overall state of the evidence, without providing any medical guidance or advice. The information is derived from regulatory documentation and scientific reviews.

Evidence for Use in Painful Muscle Contractures

Research examining the use of Myozepam for painful muscle contractures primarily relies on a small number of short-term, double-blind clinical trials. These studies were applied in research contexts involving fluctuating or unstable symptoms, where Tetrazepam was evaluated alongside a placebo over defined time intervals. In these trials, researchers examined outcomes related to physical discomfort, specifically measuring changes in pain intensity and assessing the severity of muscle spasm or hypertonia.

Studies reported measurements of symptom change, and findings from some trials described patterns where the difference between the Tetrazepam and placebo groups was minimal. Scientific reviews suggest that the overall body of evidence is limited due to the small sample sizes of the core efficacy trials. There is limited information for long-term outcomes when managing these acute conditions.

Evidence for Use in Spasticity (Excessive Muscle Stiffness)

The research base for spasticity consists mainly of Randomized Controlled Trials (RCTs). These studies were structured as comparative studies, where researchers evaluated Tetrazepam alongside other established oral medicines for spasticity. The studies monitored clinical outcomes, examining measures such as differences in standardized spasticity scale scores and the measurement of muscle tone during the observation period. In these comparative settings, data show patterns related to measured outcomes being comparable between Tetrazepam and the other active treatments used in the research.

The evidence for spasticity is categorized as low certainty. A key limitation is that the available studies reported no measurable differentiation in outcomes, meaning comparative evidence is lacking to indicate differentiation in outcomes.

What is Still Uncertain About Myozepam’s Research Base

Based on regulatory and scientific reviews, research on Myozepam has several acknowledged limitations. Evidence quality varies across studies, and the certainty remains low for several findings. A key uncertainty stems from the reliance on small sample sizes in some of the core efficacy trials. Comparative evidence is lacking to clearly distinguish its profile from other established treatments, particularly for spasticity. Furthermore, the focus on acute conditions means that long-term outcomes and the effect in chronic settings are not well characterized by the current body of research.

Frequently Asked Questions (FAQ)

Common questions about Myozepam (FAQ)

Q: How quickly does Myozepam typically start working after taking it?

A: Official information derived from pharmacokinetic data indicates that the active substance is quickly absorbed after being taken by mouth. It typically reaches its highest measured levels in the bloodstream, known as peak plasma concentration, in less than two hours. This characteristic suggests that the active substance starts to work relatively quickly.

Q: How long does the effect of a Myozepam dose last?

A: The duration the substance remains active in the body is described by its elimination half-life, which is approximately 15 to 22 hours. The half-life refers to the time it takes for half of the medicine to be eliminated. Because of this duration, Myozepam is classified as an intermediate half-life agent.

Q: Can Myozepam cause you to feel drowsy the next day?

A: Drowsiness is a common and expected side effect of this medicine, as it acts as a central nervous system depressant. Due to its half-life, official documents note that users may still experience residual drowsiness the day after taking a dose, consistent with the timing of evening administration mentioned in the product information.

Q: Is Myozepam commonly prescribed for long-term use?

A: The official administration instructions strictly emphasize that treatment with Myozepam must be limited to the shortest possible duration. This aligns with its authorized use for short-term, acute conditions, with some guidelines citing a maximum treatment course of 3 weeks to 3 months.

Q: Does Myozepam have any effect on blood pressure?

A: The safety profile for this class of medicine includes the potential for cardiovascular effects. Though not listed as a common reaction, reports have documented effects such as a temporary lowering of blood pressure (hypotension), as noted in the safety profile for the drug class.

Q: Is there a risk of developing tolerance to Myozepam over time?

A: Official documents for this drug class acknowledge that physical dependence may develop with regular use, even over short periods. Dependence can be associated with a need for dose adjustments to achieve the intended effect, which is a characteristic related to dependence.

Q: Can Myozepam cause changes in appetite or weight?

A: Adverse event data for this medicine’s class includes various metabolic and gastrointestinal effects. While considered less common than its CNS effects, regulatory profiles have documented changes such as loss of appetite (anorexia) or other related gastrointestinal disturbances.

Q: Can Myozepam be taken while breastfeeding?

A: Official regulatory documents clearly classify the medicine as Not Recommended during breastfeeding. This is because the active substance is known to be excreted into breast milk, due to the documented potential risks associated with the substance transferring to the infant.

Q: Why does the official guidance advise caution with alcohol when taking Myozepam?

A: Official guidance advises caution because co-ingestion with alcohol is documented to amplify the central nervous system (CNS) depressant outcomes of the medicine. The interaction increases the risk of enhanced CNS depressant effects, such as increased sedation.

Q: Why is Myozepam sometimes prescribed for people with seizure conditions?

A: As a member of the benzodiazepine class, the drug enhances inhibitory nerve signaling in the brain, which gives it documented anticonvulsant properties. The official therapeutic use is principally focused on managing muscle contractures and muscle relaxation.

Q: Are headaches a known side effect of Myozepam?

A: While not among the most commonly reported reactions, official regulatory profiles for this drug class do include reports of headache as a possible, though less frequent, adverse effect.

Q: Does Myozepam have a sedative effect?

A: Yes, Myozepam is structurally classified as a central nervous system (CNS) depressant. The most frequently documented side effects in official sources, such as drowsiness and dizziness, are direct manifestations of this inherent sedative action.

Q: Can taking Myozepam affect the results of blood tests?

A: The safety profile includes a documented, although very rare, risk of hepatotoxicity and liver failure. The possibility of severe hepatotoxicity, a very rare adverse effect, may be associated with changes in certain blood tests.

Q: What does the term 'half-life' mean in relation to Myozepam?

A: In pharmacology, the half-life refers to the period of time required for the amount of active substance present in the body to be reduced by half. For Myozepam, the reported elimination half-life is approximately 15 to 22 hours.

Q: Is Myozepam used in emergency settings?

A: The official indication for Myozepam is the treatment of muscle contractures and spasticity. While other drugs in the benzodiazepine class are used in some neurological emergencies, this specific drug is not documented by regulatory bodies for routine use in acute emergency settings.

Q: Does Myozepam cause confusion in some patients?

A: Confusion is a documented central nervous system adverse effect associated with this class of medicines. The regulatory information notes that this risk is greater in certain sensitive populations, such as older adults.

Q: Can Myozepam be taken if I am planning to become pregnant?

A: Official regulatory guidance advises against the use of the drug in women who are pregnant or who are planning to become pregnant. This precaution is based on the documented potential risks for the fetus associated with the substance and its drug class.

Q: What is the general patient expectation regarding Myozepam's effectiveness?

A: Research evidence indicates that for painful muscle contractures, the difference in measured outcomes was sometimes described as minimal compared to a placebo. For spasticity, outcomes were generally found to be comparable to those achieved with other active treatments used in the research.

Q: Are allergic reactions to Myozepam possible?

A: Yes, official safety information documents the possibility of severe hypersensitivity events. These include serious allergic reactions such as Anaphylactic shock, and the potential for severe cutaneous adverse reactions (SCARs) is also noted in regulatory documentation.

Q: Is Myozepam available in different forms besides tablets?

A: The drug is officially supplied for oral administration, primarily in the form of tablets or film-coated tablets, consistent with its labeled use and is indicated for the treatment of muscle contractures and spasticity.

Q: Can Myozepam make symptoms of depression worse?

A: Official safety data for this class of medicine includes the possibility of changes in mood or psychiatric disturbances. Official regulatory profiles document the worsening of existing psychiatric symptoms, such as depression, as a potential adverse effect.

Q: Does Myozepam affect your memory?

A: Yes, regulatory documents for this drug class note that effects on memory are possible central nervous system effects. This may include anterograde amnesia (difficulty recalling new information).

Q: What evidence supports the use of Myozepam in different patient groups?

A: The available clinical evidence primarily focuses on the acute conditions of muscle contractures and spasticity in the general adult population. Official regulatory reviews acknowledge that long-term outcomes and the drug's effects in chronic settings or specific sub-populations are not well characterized by the current body of research.

How should Myozepam be stored and disposed of?

How to Store and Dispose of Myozepam?

Because Myozepam (Tetrazepam) is a prescription medicine and a controlled substance, official regulatory guidance mandates specific storage and disposal rules to maintain its quality and prevent unauthorized access.

Storage Requirement	Official Mandate
Temperature & Packaging	Store in the original container, tightly closed, at Controlled Room Temperature, typically not exceeding 30 C. Protect from moisture.
Security	The medicine must be stored locked up and kept securely out of the sight and reach of children and unauthorized individuals.
Disposal	Do not flush the product down the toilet or discard it into drains; disposal must follow official government protocols, such as drug take-back programs, to avoid environmental discharge.

Myozepam